TY - JOUR
T1 - Perspectives for systems biology in the management of tuberculosis
AU - Kontsevaya, Irina
AU - Lange, Christoph
AU - Comella-Del-barrio, Patricia
AU - Coarfa, Cristian
AU - Dinardo, Andrew R.
AU - Gillespie, Stephen H.
AU - Hauptmann, Matthias
AU - Leschczyk, Christoph
AU - Mandalakas, Anna M.
AU - Martinecz, Antal
AU - Merker, Matthias
AU - Niemann, Stefan
AU - Reimann, Maja
AU - Rzhepishevska, Olena
AU - Schaible, Ulrich E.
AU - Scheu, Katrin M.
AU - Schurr, Erwin
AU - Wiesch, Pia Abel Zur
AU - Heyckendorf, Jan
N1 - Publisher Copyright:
© The authors 2021.
PY - 2021/6/30
Y1 - 2021/6/30
N2 - Standardised management of tuberculosis may soon be replaced by individualised, precision medicine-guided therapies informed with knowledge provided by the field of systems biology. Systems biology is a rapidly expanding field of computational and mathematical analysis and modelling of complex biological systems that can provide insights into mechanisms underlying tuberculosis, identify novel biomarkers, and help to optimise prevention, diagnosis and treatment of disease. These advances are critically important in the context of the evolving epidemic of drug-resistant tuberculosis. Here, we review the available evidence on the role of systems biology approaches – human and mycobacterial genomics and transcriptomics, proteomics, lipidomics/metabolomics, immunophenotyping, systems pharmacology and gut microbiomes – in the management of tuberculosis including prediction of risk for disease progression, severity of mycobacterial virulence and drug resistance, adverse events, comorbidities, response to therapy and treatment outcomes. Application of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach demonstrated that at present most of the studies provide “very low” certainty of evidence for answering clinically relevant questions. Further studies in large prospective cohorts of patients, including randomised clinical trials, are necessary to assess the applicability of the findings in tuberculosis prevention and more efficient clinical management of patients.
AB - Standardised management of tuberculosis may soon be replaced by individualised, precision medicine-guided therapies informed with knowledge provided by the field of systems biology. Systems biology is a rapidly expanding field of computational and mathematical analysis and modelling of complex biological systems that can provide insights into mechanisms underlying tuberculosis, identify novel biomarkers, and help to optimise prevention, diagnosis and treatment of disease. These advances are critically important in the context of the evolving epidemic of drug-resistant tuberculosis. Here, we review the available evidence on the role of systems biology approaches – human and mycobacterial genomics and transcriptomics, proteomics, lipidomics/metabolomics, immunophenotyping, systems pharmacology and gut microbiomes – in the management of tuberculosis including prediction of risk for disease progression, severity of mycobacterial virulence and drug resistance, adverse events, comorbidities, response to therapy and treatment outcomes. Application of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach demonstrated that at present most of the studies provide “very low” certainty of evidence for answering clinically relevant questions. Further studies in large prospective cohorts of patients, including randomised clinical trials, are necessary to assess the applicability of the findings in tuberculosis prevention and more efficient clinical management of patients.
UR - http://www.scopus.com/inward/record.url?scp=85106866948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106866948&partnerID=8YFLogxK
U2 - 10.1183/16000617.0377-2020
DO - 10.1183/16000617.0377-2020
M3 - Review article
C2 - 34039674
AN - SCOPUS:85106866948
SN - 0905-9180
VL - 30
JO - European Respiratory Review
JF - European Respiratory Review
IS - 160
M1 - 200377
ER -